Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based Investigation in Cooperation With the International Society for Dermatologic and Aesthetic Surgery (ISDS)
April 2021 | Volume 20 | Issue 4 | Original Article | 374 | Copyright © April 2021
Published online February 24, 2021
Robert H. Gotkin MDa*, Uliana Gout MDb*, Sonja Sattler MDc*, Miriam Emily Piansay-Soriano MDd*, Rungsima Wanitphakdeedecha MD, MA, MSe*, Sahar Ghannam MD, PhDf*, Elena Rossi MDg*, Teresita S. Ferrariz MDh*, Doris Hexsel MDi*, Konstantin Frank MDj, Kristina Davidovic MDk, Deborah S. Sarnoff MDl*, Sebastian Cotofana MD PhDm
*For the International Society for Dermatologic and Aesthetic Surgery (ISDS)
aPrivate Practice, New York, NY, United States
bPrivate Practice, London, United Kingdom
cPrivate Practice, Darmstadt, Germany
dDepartment of Dermatology, Davao Medical School Foundation, Davao City, Philippines
eDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
fPrivate Practice, Kuwait and Department of Dermatology, Venereology and Andrology, Alexandria University, Egypt
gDepartment of Dermatology, Head and Neck Cancer Service, Modena and Reggio Emilia University, Modena, Italy
hGwapaha Advanced Medical Aesthetics Centre, Makati City, Philippines
iBrazilian Center for Studies in Dermatology, Porto Alegre, Brazil
jDepartment for Hand, Plastic and Aesthetic Surgery, Ludwig – Maximilian University Munich, Germany
kDepartment of Radiology & Medical School, University of Belgrade, Serbia
lDepartment of Dermatology, NYU Langone Medical Center and Private Practice, New York, NY, United States
mDepartment of Clinical Anatomy, Mayo Clinic College of Medicine and Science, Rochester, MN, United States
Methods: A global survey was designed to capture the incidence of adverse events related to: (1) previous soft tissue filler injections, (2) soft tissue filler injections during positive testing for COVID-19, and (3) soft tissue filler injections during and after receiving any of the COVID-19 vaccines globally available.
Results: The information of 106 survey participants from 18 different countries was analyzed. 80.2% (n=85) never experienced any adverse reaction following their soft tissue filler injection whereas 15.1% (n=16) experienced swelling and 4.7% (n=5) experienced pain that lasted longer than two days. Of those who received at least one dose of the COVID-19 vaccine (n=78), 94.9% reported not to have experienced any adverse reaction related to their previous soft tissue filler injection, whereas 5.1% (n=4) reported to have perceived pain that lasted longer than two days.
Conclusion: The data collected does not support the concern for an increased risk of developing adverse reactions following soft tissue filler injections associated with the COVID-19 vaccines compared to that risk associated with other previously described triggers or the default risk following soft tissue filler injections.
J Drugs Dermatol. 20(4):374-378. doi:10.36849/JDD.2021.6041